Parx Plastics, a developer of antibacterial plastics headquartered in Rotterdam in the Netherlands, has announced on target results for its innovative antibacterial technology with BASF's Terluran GP-35 ABS copolymer. Terluran is a standard ABS grade material with a low viscosity and a wide range of applications.
Terluran GP-35 is available throughout the world and now with the aid of Parx Plastics' patented technology can incorporate an effective antimicrobial property. Its effectiveness can reach 98–99% after 24 hours, the firm says, following ISO 22196 or JIS Z 2801 testing guidelines and works effectively against Staphylococcus Aureus, Escherichia Coli, MRSA, Clostridium Difficile and many other bacteria.
Parx Plastics' technology allows the creation of Sanipolymers by incorporating one of the most abundant trace elements in the human body inside the polymers, rather than integrate it as a nanoparticle, and thereby provide a highly effective antibacterial property.
The technology can be applied to any (co-)polymer and the firm says it offers a safe and non-toxic alternative to currently available solutions such as (nano-)silver, chemicals (e.g. Triclosan) or solutions by means of nano-particles.
